Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
Not Confirmed
Not Confirmed
17-21 January, 2026
Not Confirmed
Not Confirmed
21-22 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
Industry Trade Show
Not Confirmed
17-21 January, 2026
Industry Trade Show
Not Confirmed
21-22 January, 2026
Digital content
NEWS #PharmaBuzz
16 Nov 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/11/16/2782197/0/en/Better-Choice-Research-Partner-Aimia-Pet-HealthCo-Inc-Signs-Second-R-D-Partnership-Agreement-with-KGK-Science-for-Development-of-GLP1-Supplement-for-Pets.html
11 Apr 2023
// BUSINESSWIRE
15 Feb 2023
// BUSINESSWIRE
06 Dec 2022
// BUSINESSWIRE
30 Nov 2022
// BUSINESSWIRE
Drugs in Development
Details:
VitaDry-Q10 is a dietary supplement, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Lead Product(s): VitaDry-Q10,VitaSperse-Q10,Coenzyme Q10
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Dietary Supplement
Recipient: 3i Solutions
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 28, 2025
Lead Product(s) : VitaDry-Q10,VitaSperse-Q10,Coenzyme Q10
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : 3i Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VitaDry-Q10 is a dietary supplement, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
November 28, 2025
Details:
AMPK Charge Plus is a Dietary Supplement drug candidate, which is currently being evaluated in Undisclosed clinical studies for the treatment of Prediabetic State.
Lead Product(s): AMPK Charge Plus
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Dietary Supplement
Recipient: QuickSilver Scientific
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 29, 2025
Lead Product(s) : AMPK Charge Plus
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Recipient : QuickSilver Scientific
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AMPK Charge Plus is a Dietary Supplement drug candidate, which is currently being evaluated in Undisclosed clinical studies for the treatment of Prediabetic State.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
September 29, 2025
Details:
Collagen Hydrolysate is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of unspecified medical condition.
Lead Product(s): Collagen Peptide
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Protein
Recipient: Rousselot BVBA
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 29, 2025
Lead Product(s) : Collagen Peptide
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : Rousselot BVBA
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Nextida GC-B on Glycemic Control in Normoglycemic & Prediabetic Adults
Details : Collagen Hydrolysate is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of unspecified medical condition.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 29, 2025
Details:
Apple Cider Vinegar is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of unspecified medical condition.
Lead Product(s): Apple Cider Vinegar
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Plant Extract/Herbal
Recipient: Bragg Live Food Products
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 03, 2025
Lead Product(s) : Apple Cider Vinegar
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : Bragg Live Food Products
Deal Size : Inapplicable
Deal Type : Inapplicable
Bragg Apple Cider Vinegar Supplement Effect On Blood Glucose In Healthy Adults
Details : Apple Cider Vinegar is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of unspecified medical condition.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
August 03, 2025
Details:
Lysophosphatidylcholine-Rich Oil Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Cognitive Dysfunction.
Lead Product(s): Lysophosphatidylcholine-Rich Oil Extract
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Plant Extract/Herbal
Recipient: Aker BioMarine
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 24, 2025
Lead Product(s) : Lysophosphatidylcholine-Rich Oil Extract
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Recipient : Aker BioMarine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lysoveta Trial to Assess Cognitive Function in Healthy Adult with Memory Complaints
Details : Lysophosphatidylcholine-Rich Oil Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Cognitive Dysfunction.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
June 24, 2025
Details:
Lipase Thera-Blend is a Enzyme drug candidate, which is currently being evaluated in clinical studies for the treatment of Neurocognitive Disorders.
Lead Product(s): Lipase Thera-Blend,Tributyrin
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Enzyme
Recipient: Enzymedica
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 13, 2025
Lead Product(s) : Lipase Thera-Blend,Tributyrin
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Recipient : Enzymedica
Deal Size : Inapplicable
Deal Type : Inapplicable
Lipase Thera-blend ± Tributyrin Effect on Memory in Healthy Adults
Details : Lipase Thera-Blend is a Enzyme drug candidate, which is currently being evaluated in clinical studies for the treatment of Neurocognitive Disorders.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
June 13, 2025
Details:
AlphaWave L-Theanine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Cognition.
Lead Product(s): L-Theanine
Therapeutic Area: Neurology Brand Name: AlphaWave L-Theanine
Study Phase: UndisclosedProduct Type: Amino Acid
Recipient: Ethical Naturals, Inc.
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 04, 2025
Lead Product(s) : L-Theanine
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Recipient : Ethical Naturals, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Alphawave L-Theanine For Cognitive Function In Moderately Stressed Adults
Details : AlphaWave L-Theanine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Cognition.
Product Name : AlphaWave L-Theanine
Product Type : Amino Acid
Upfront Cash : Inapplicable
June 04, 2025
Details:
Delta 9 Tetrahydrocannabinol is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Marijuana Abuse.
Lead Product(s): Delta 9 Tetrahydrocannabinol
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Undisclosed
Recipient: Sobereye Inc.
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 13, 2025
Lead Product(s) : Delta 9 Tetrahydrocannabinol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Recipient : Sobereye Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Delta 9 Tetrahydrocannabinol is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Marijuana Abuse.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 13, 2025
Details:
Humiome Post Lb is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Gastrointestinal Diseases.
Lead Product(s): Humiome Post Lb
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Dietary Supplement
Recipient: Royal DSM
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 22, 2025
Lead Product(s) : Humiome Post Lb
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Recipient : Royal DSM
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effect of Humiome® Post LB on Gut COMFort in healthY Adult Volunteers
Details : Humiome Post Lb is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Gastrointestinal Diseases.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
April 22, 2025
Details:
Graminex Wspe is a Dietary Supplement drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Menopause.
Lead Product(s): Graminex Wspe
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Dietary Supplement
Recipient: Graminex LLC
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 21, 2025
Lead Product(s) : Graminex Wspe
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Recipient : Graminex LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Graminex Wspe is a Dietary Supplement drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Menopause.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
March 21, 2025
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
